| NCT07116694 | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder | ACTIVE_NOT_RECRUITING | PHASE2 | 2025-06-19 | 2025-10 | 2025-10 |
| NCT06041646 | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder | COMPLETED | PHASE4 | 2023-10-12 | 2024-04-29 | 2024-04-29 |
| NCT05665088 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) | TERMINATED | PHASE3 | 2022-12-14 | 2023-09-11 | 2023-09-11 |
| NCT05658510 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) | COMPLETED | PHASE3 | 2022-11-21 | 2025-08-15 | 2025-08-15 |
| NCT05271552 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) | COMPLETED | PHASE3 | 2022-04-27 | 2023-04-21 | 2023-04-21 |
| NCT05276830 | An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia | TERMINATED | PHASE2 | 2022-02-08 | 2022-04-01 | 2022-04-01 |
| NCT05025605 | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder | RECRUITING | PHASE1 | 2021-08-27 | 2026-12-31 | 2026-07-31 |
| NCT05313386 | Study of BXCL501 In Agitation Associated With Delirium in ICU Patients | WITHDRAWN | PHASE2 | 2021-02-23 | 2022-02-21 | 2022-02-21 |
| NCT04470050 | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal | COMPLETED | PHASE1, PHASE2 | 2020-06-09 | 2021-02-18 | 2021-02-18 |
| NCT04276883 | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder | COMPLETED | PHASE3 | 2020-02-24 | 2020-05-21 | 2020-05-21 |
| NCT04268303 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia | COMPLETED | PHASE3 | 2020-01-24 | 2020-05-06 | 2020-05-06 |
| NCT04251910 | Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia | COMPLETED | PHASE1, PHASE2 | 2019-12-27 | 2022-01-24 | 2022-01-24 |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | WITHDRAWN | EARLY_PHASE1 | 2019-10-15 | 2021-12-06 | 2021-12-06 |
| NCT04010305 | Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia | COMPLETED | PHASE1 | 2019-05-22 | 2019-07-31 | 2019-07-31 |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-02-12 | 2025-12 | 2023-10 |